KesimptaConnect

This page is intended for UK healthcare professionals currently prescribing KESIMPTA®▼ (ofatumumab), who are interested in learning more about the KesimptaConnect Programme.

KESIMPTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.1

KesimptaConnect has been developed and funded by Novartis Pharmaceuticals UK Limited. KesimptaConnect pre-initiation, nurse service and home delivery is offered as a package deal. KesimptaConnect portal is offered as a patient support programme. KesimptaConnect is for patients who are receiving KESIMPTA or for whom the prescribing decision has been made. A service-level agreement is required for each NHS organisation participating.

 

Image
KesimptaConnect logo.

Providing dedicated, personalised support to your eligible patients

Image
Circle with the number 5369.

5369 active patients, as of November 2024.2

Image
Circle with the number 83.

83 sites signed up.3

Image
Circle with the text 98%.

98% of surveyed patients (N=1003) are extremely satisfied with the KesimptaConnect Nurse service overall.4

KesimptaConnect offers dedicated, personalised support to patients and healthcare professionals throughout the KESIMPTA journey. 

Enrollment provides your patients unique access to a wide range of services, including injection support, home deliveries, tailored information and interactive content covering wider aspects of living with RMS, as well as a dedicated, experienced nurse support team. The programme has been designed to offer personalised support in conjunction with the medical care provided by your hospital’s MS team.

Healthcare professionals are also able to access a personalised support service based on the needs of their centre. 

KesimptaConnect consists of:

Image
House icon representing KesimptaConnect homecare.

1. KesimptaConnect Homecare: in line with the National Homecare Medicines Committee (NHMC) Pharma-funded Homecare Services guidelines, Novartis has commissioned Lloyds Pharmacy Clinical Homecare Limited, Pharmaxo Pharmacy Services Limited and Sciensus Limited to provide a homecare service for patients prescribed KESIMPTA.

Image
Healthcare professional icon representing KesimptaConnect nurse services.

2. KesimptaConnect Nurse services: nurses who can provide virtual or face-to-face appointments with your patients to provide injection guidance and support in the first year of each patient’s treatment journey.

Image
Mobile phone icon with the KesimptaConnect app.

3. The KesimptaConnect app: provides a hub of information and resources to your patient, including an injection tracker to support treatment adherence.

There is no obligation to use all elements of this programme; it is designed to allow you to choose the components that best suit the needs of your patient.

Discuss with your local Novartis representative which elements are right for your patients and the MS services you provide.

As part of KesimptaConnect, your patients have access to a homecare service:

Image
Sensoready pen icon.

The service will deliver the KESIMPTA pens straight to your patient’s door at a time and date that is convenient to them.
Delivery schedule: one delivery to cover the first 4 injections and from Week 8, delivery every 3 months.

Image
Pharmacy cross icon representing the homecare supplier’s prescription management system.

The Homecare suppliers have a robust prescription management system. They will proactively seek any missing prescriptions in order to ensure your patients receive their KESIMPTA at the correct time.

For ongoing deliveries from Week 8, if you or your patient prefer monthly delivery, this is also an option.

The KesimptaConnect Nurse team has experience caring for a wide range of patients with MS and have in-depth knowledge of KESIMPTA.

Once KESIMPTA has been prescribed, the nurse team can provide self-injection support, designed to ensure that your patient is both:

Image
Tick icon.

Comfortable with the self-injection technique using the KESIMPTA pen

Image
Tick icon.

Confident in injecting themselves at home

They will also keep you informed of your patient’s progress.

Each KesimptaConnect Nurse can support your patients with health psychology approaches.

Image
Phone icon representing registering patient for KesimptaConnect.

Once the decision to prescribe KESIMPTA has been made and you have registered your patient for KesimptaConnect, a KesimptaConnect Nurse will contact your patient to organise their first appointment and provide KESIMPTA pen injection guidance.

Image
Nurse icon.

The first injection of KESIMPTA should be performed under the guidance of a healthcare professional, for example, a KesimptaConnect Nurse.

Image
Person standing in a circle icon representing different methods of seeing the patient.

This service will be provided with the needs of your patient at the forefront, and offered as either face-to-face or virtual, depending on their preference. The flexibility of this service is designed to ensure that your patient is as comfortable as possible with using their KESIMPTA pen.

  • The KesimptaConnect Nurse will provide support using a self-injection demonstration kit and answer any further questions your patient may have

  • At the first appointment, the KesimptaConnect Nurse will conduct personalisation screening, to understand the patient’s support needs, agree a contact schedule with the patient and arrange the next call or visit

  • The KesimptaConnect Nurse will make contact with the patient ahead of each scheduled injection for the first 12 weeks to check on confidence with self-injection and provide personalised support

  • Subsequent interactions will be determined by the patient and KesimptaConnect Nurse (as required) for up to 12 months

  • Visit summaries will be sent to you by the KesimptaConnect Nurse after each patient interaction to keep you informed of your patient’s progress

  • Injection reminders can be set up by the KesimptaConnect Nurse so that the patient is sent SMS reminders one day before and on the day their injection is due. This option will be discussed with the patient at the first appointment

The service will ensure that your patient is adequately supported until they are comfortable with their once-monthly self-administration.

Once your patient is comfortable, they will also be supported in accessing the designated KesimptaConnect App for further ongoing support.

For more information and details on how to enrol your patients in the KesimptaConnect programme, please speak to your local Novartis representative.

The KesimptaConnect app provides educational support and resources tailored to each patient, including:

Image
Image representing the login screen of the KesimptaConnect app.
Image
Image representing the injection tracker screen of the KesimptaConnect app.

 

  • Information on KESIMPTA to empower your patient to understand their MS and provide tools to help them manage it

  • MS management support to provide articles and interactive content on wider aspects of living with MS (e.g., managing fatigue, emotional wellbeing, keeping active, work)

  • Injection reminders and tracking will enable your patients to track when to take their injection, record when they took injections and which injection site was used

The KesimptaConnect nurse will support the patient in accessing the app, which is available on both mobile phone and web browsers.

Should you wish to find out more about the app please reach out to your local Novartis representative.

KesimptaConnect checklist

Set up

Sign the Overview and Offer Form with Novartis Pharmaceuticals UK Ltd

Sign the Programme Authorisation Document with IQVIA IES UK Ltd

Sign the Service Level Agreement with your Homecare partner of choice

Once KESIMPTA has been chosen as the treatment of choice

Make your patient aware of the KesimptaConnect service and choose the elements that would be best for your patient

Homecare

Register your patient for KesimptaConnect by contacting the relevant Homecare company

Injection support and nurse services

Register your patient for KesimptaConnect injection support and nurse services by emailing the completed patient registration form to [email protected]

KesimptaConnect App

Register your patient for the KesimptaConnect App by emailing the completed patient registration form to [email protected]


View the KesimptaConnect touchpoints below

Image
Graphic indicating the KesimptaConnect touchpoints.

*Homecare: initial phase – one delivery for first 4 injections, ongoing – delivery every 3 months after initiation. For ongoing, if you or your patient prefer monthly delivery, this is also an option.
The first injection should be performed under the guidance of the KesimptaConnect Nurse or appropriately trained HCP.
As required by the patient. Nurse completes assessment questionnaire to determine the level of support the patient needs.

MS, multiple sclerosis; NHS, National Health Service; NHMC, national homecare medicines committee; RMS, relapsing forms of multiple sclerosis.

References

  1. KESIMPTA (ofatumumab) Summary of Product Characteristics.

  2. Novartis Data on File, OFA231, 2025.

  3. Novartis Data on File, OFA019, 2024.

  4. Novartis Data on File, OFA017, 2024.

UK | March 2025 | FA-11213993

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.